This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Essential Hypertension
and you are
over 20
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

This study assessed the efficacy of LCZ696 in Japanese patients with essential hypertension

Provided treatments

  • Drug: LCZ696
  • Drug: Olmesartan
  • Drug: Placebo
Tris trial is registered with FDA with number: NCT01599104. The sponsor of the trial is Novartis Pharmaceuticals and it is looking for 1161 volunteers for the current phase.
Official trial title:
A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension